Company news
Shanghai Serum Bio-technology Co., Ltd. Class A (SSE:688163) news
Shanghai Serum Bio-technology Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: "SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD."Announcement…
Press releases & updates
"SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
September 28, 2026
"SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Certificate of GMP Compliance from the Philippines
September 24, 2026
"SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD."Announcement on Departure of a Director, Senior Management Member and Core Technical Personnel, By-election of a Director and Adjustment of Core Technical Personnel
September 11, 2026
"SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026
September 8, 2026
"SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Biological Products and CXO Industry
September 3, 2026
"SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD."Announcement on the Profit Distribution Plan for the First Half of 2026
August 21, 2026
Announcement on Change of Secretary of the Board of Directors
June 8, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 22, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 15, 2026
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Anti-bee Venom Serum
May 7, 2026
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
April 28, 2026
Announcement on Renewing Engagement of Audit Institution for 2026
April 24, 2026
Announcement on Using Self-owned Funds to Pay Personnel Expenses for Investment Projects Financed by Raised Funds and Replacing with Equal Raised Funds
March 20, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 26, 2026
Announcement on Changing Signatory Certified Public Accountant
December 25, 2025
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
November 3, 2025
Report for Q3 2025
October 27, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 19, 2025
Announcement on Attending Semi-annual Collective Performance Briefing for Enterprises in Biological Products and CXO Industries on SSE STAR Market 2025
September 4, 2025
Announcement on Listing and Circulation of Restricted Shares in Initial Public Offering
September 3, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 25, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
August 11, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
July 24, 2025
Announcement on Closing Some Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Permanently Supplement Current Capital and Canceling Relevant Special Accounts for Raised Funds
June 18, 2025
Announcement on Implementation of Dividend Distribution for 2024
May 27, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 16, 2025
Announcement on the Remuneration Plan for Directors, Supervisors and Senior Management Members in 2025
April 25, 2025
Announcement on Convening Performance Meeting for 2024 and 1st Quarter of 2025
April 21, 2025
Announcement on Changing Project Quality Control Reviewer of Audit Institution
April 8, 2025
Announcement on Using Some Temporarily Idle Raised Funds for Cash Management
March 20, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 25, 2025
Announcement on Change of Chief Financial Officer
February 7, 2025
Announcement on Provision for Impairment of Long-term Equity Investment
November 22, 2024
Report for Q3 2024
October 25, 2024
Announcement on Convening Q3 2024 Performance Briefing
October 21, 2024
Announcement on Resolution of the 1st Extraordinary General Meeting in 2024
September 30, 2024
Announcement on Convening 2024 Semi-annual Performance and Cash Dividend Briefing
September 18, 2024
Notice on Convening the 1st Extraordinary General Meeting in 2024
September 13, 2024
Announcement on Implementation of Dividend Distribution for Half Year of 2024
September 5, 2024
Announcement on the 2024 Semi-annual Profit Distribution Plan
August 27, 2024
Announcement on the Completion of the Implementation of the Shareholding Increase Plan for One of the Actual Controllers, Director, General Manager and Some Senior Executives and Results of Share Increase
August 15, 2024
Indicative Announcement on Postponing Term Change of Board of Directors and Board of Supervisors
August 5, 2024
Announcement on Receiving Proposals from the Chairman and One of the Actual Controllers to Implement the 2024 Interim Dividend and the "Corporate Value and Return Enhancement" Action Plan
July 16, 2024
Announcement on Implementation of Dividend Distribution of 2023
May 27, 2024
Announcement on Resolutions of 2023 Annual General Meeting
May 20, 2024
Announcement on Attending Biological Product Special Session of 2023 Annual Collective Performance Meeting and 2024 1st Quarter Performance Meeting
May 14, 2024
Announcement on Renewing Engagement of Audit Institution of 2024
April 26, 2024
Announcement on Progress in Shareholding Increase by One of Actual Controllers, Director, General Manager and Some Senior Management Members
March 6, 2024
Announcement on Circulation of Restricted Shares under Strategic Allotment in Initial Public Offering
March 1, 2024
Announcement on Shareholding Increase Plan of One of Actual Controllers, Director, General Manager and Some Senior Management Members
February 23, 2024